SEC Form 4 · accession 0001536368-26-000004
Enliven Therapeutics, Inc. · ELVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lori Anne Kunkel
Director
Period of report
Jun 5, 2026
Accepted (ET)
Jun 9, 2026 · 4:49 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001672619
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jun 5, 2026 | S | 7,779 | $34.2794 | D | 54,105 | D | |
| Common StockF4 | Jun 5, 2026 | S | 1,867 | $35.3573 | D | 52,238 | D | |
| Common StockF5 | Jun 5, 2026 | S | 354 | $35.8187 | D | 51,884 | D | |
| Common StockF3,F6 | holding | — | — | — | 0 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026
- F2This transaction was executed in multiple trades at prices ranging from $33.7383 to $34.7358. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F3The number of shares held reflects the transfer of 31,172 shares of Common Stock from Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE to the Reporting Person .
- F4This transaction was executed in multiple trades at prices ranging from $34.759 to $35.7574. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F5This transaction was executed in multiple trades at prices ranging from $35.7595 to $35.9456. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F6The shares were held by Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE.